Alnylam Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Achieved full-year GAAP profitability in 2025, a landmark transition driven by 81% year-over-year growth in net product revenues.
The TTR franchise delivered $858 million in Q4, representing 151% growth year-over-year, primarily fueled by the U.S. launch of Amvuttra for ATTR cardiomyopathy.
Amvuttra has approached parity with tafamidis in share of new treatment starts by its second full quarter post-launch, signaling a shift in prescribing dynamics.
Launched Cyrillis, a proprietary enzymatic ligation-based manufacturing platform designed to expand capacity and reduce cost of goods for RNAi therapeutics.
Management attributes commercial success to broad first-line payer access, with over 90% of payers providing coverage without step-through requirements.
The Alnylam 2030 strategy aims for a 25% revenue CAGR and 30% non-GAAP operating margins, leveraging a pipeline of over 25 clinical programs.

2026 TTR revenue guidance of $4.4 billion to $4.7 billion assumes continued brisk category growth and a mid-single-digit net price decrease in the U.S.
Anticipate a Q1 2026 revenue headwind due to pricing alignment in Germany for the cardiomyopathy launch and annual U.S. insurance reauthorizations.
Expect to share clinical de-risking data in the second half of 2026 for Huntington’s disease (ALN-HTT02) and obesity (ACVR1C) programs.
The 2030 roadmap includes launching nuceresiran, which lacks royalty obligations and is expected to drive operating margins toward the mid-40s post-2030.
Planned R&D investment will remain at approximately 30% of revenues to accelerate organic innovation and selectively access external technologies.

Gross margin on product sales decreased to 77% in 2025 due to higher royalty tiers payable to Sanofi as Amvuttra revenues scaled.
International TTR revenue growth in 2026 is expected to be consistent with 2025, tempered by lower launch pricing for cardiomyopathy in European markets.
Collaboration revenue is projected to decline 38% in 2026 because a one-time $300 million milestone from the zalesiran program will not recur.
Management flagged potential near-term ‘choppiness’ in Q1 results due to fewer shipping weeks and seasonal insurance dynamics.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.

Management believes they are well-positioned to manage future competition due to established first-line access and a 25% CAGR goal that already accounts for market entrants.
Confirmed that value-based agreements have seen minimal utilization to date, supporting stable net pricing despite broader access.